Drug Profile
Research programme: Staphylococcus aureus vaccine and antibody therapeutics - Absynth
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Absynth Biologics
- Class Bacterial vaccines; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections(Prevention) in United Kingdom (Parenteral)
- 03 Sep 2010 Absynth Biologics entered into a licensing and collaboration agreement with MorphoSys for a Staphylococcus aureus vaccine and Antibody therapeutics programme